Total Payments
$23,550
2023 Payments
$15.95
Companies
5
Transactions
11
Medicare Patients
3,061
Medicare Billing
$135,589
Payment Breakdown by Category
Research$23,475 (99.7%)
Food & Beverage$75.07 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23,475 | 8 | 99.7% |
| Food and Beverage | $75.07 | 3 | 0.3% |
Payments by Type
Research
$23,475
8 transactions
General
$75.07
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $23,375 | 7 | $0 (2018) |
| Celltrion, Inc. | $100.00 | 1 | $0 (2017) |
| Endologix, Inc. | $37.85 | 1 | $0 (2018) |
| BIOTRONIK INC. | $21.27 | 1 | $0 (2022) |
| Amgen Inc. | $15.95 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $15.95 | 1 | Amgen Inc. ($15.95) |
| 2022 | $21.27 | 1 | BIOTRONIK INC. ($21.27) |
| 2018 | $7,575 | 5 | NOVARTIS PHARMACEUTICALS CORPORATION ($7,538) |
| 2017 | $15,938 | 4 | NOVARTIS PHARMACEUTICALS CORPORATION ($15,838) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/11/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Cardiology | ||||||
| 04/27/2022 | BIOTRONIK INC. | Edora 8 DR-T (Device) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/08/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | LJN452 (Drug) | — | Cash or cash equivalent | $187.50 | Research |
| Study: A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 2 PART ADAPTIVE DESIGN MULTICENTER 12 WEEK STUDY TO ASSESS SAFETY TOLERABILITY AND EFFICACY OF LJN452 IN PATIENTS WITH NON ALCOHOLIC STEATOHEPETATIS NASH | ||||||
| 07/06/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | BIMAGRUMAB (Biological) | — | Cash or cash equivalent | $125.00 | Research |
| Study: A 28 WEEK RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTI CENTER PARALLEL GROUP DOSE RANGE FINDING STUDY TO ASSESS THE EFFECT OF MONTHLY DOSES OF BIMAGRUMAB 70 210 AND 700 MG ON SKELETAL MUSCLE STRENGTH AND FUNCTION IN OLDER ADULTS WITH SARCOPENIA | ||||||
| 03/09/2018 | Endologix, Inc. | Ovation (Device) | Food and Beverage | In-kind items and services | $37.85 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/10/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | BIMAGRUMAB (Biological) | — | Cash or cash equivalent | $3,787.50 | Research |
| Study: AN OPEN LABEL LONG TERM STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF BYM338 IN PATIENTS WITH SPORADIC INCLUSION BODY MYOSITIS | ||||||
| 01/10/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | BIMAGRUMAB (Biological) | — | Cash or cash equivalent | $3,437.50 | Research |
| Study: A RANDOMIZED MULTI CENTRE DOUBLE BLIND PLACEBO CONTROLLED PHASE IIB TO EVALUATE THE SAFETY AND EFFICACY OF IV BYM338 ON FUNCTION MOBILITY AND FALL REDUCTION IN PATIENTS AFTER SURGICAL TREATMENT OF HIP FRACTURE | ||||||
| 11/09/2017 | Celltrion, Inc. | — | — | Cash or cash equivalent | $100.00 | Research |
| Study: CT-P6 3.2 | ||||||
| 04/10/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | BIMAGRUMAB (Biological) | — | Cash or cash equivalent | $375.00 | Research |
| Study: AN OPEN LABEL LONG TERM STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF BYM338 IN PATIENTS WITH SPORADIC INCLUSION BODY MYOSITIS | ||||||
| 01/05/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | BIMAGRUMAB (Biological) | — | Cash or cash equivalent | $13,825.00 | Research |
| Study: A RANDOMIZED MULTI CENTRE DOUBLE BLIND PLACEBO CONTROLLED PHASE IIB TO EVALUATE THE SAFETY AND EFFICACY OF IV BYM338 ON FUNCTION MOBILITY AND FALL REDUCTION IN PATIENTS AFTER SURGICAL TREATMENT OF HIP FRACTURE | ||||||
| 01/05/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | BIMAGRUMAB (Biological) | — | Cash or cash equivalent | $1,637.50 | Research |
| Study: A 28 WEEK RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTI CENTER PARALLEL GROUP DOSE RANGE FINDING STUDY TO ASSESS THE EFFECT OF MONTHLY DOSES OF BIMAGRUMAB 70 210 AND 700 MG ON SKELETAL MUSCLE STRENGTH AND FUNCTION IN OLDER ADULTS WITH SARCOPENIA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED MULTI CENTRE DOUBLE BLIND PLACEBO CONTROLLED PHASE IIB TO EVALUATE THE SAFETY AND EFFICACY OF IV BYM338 ON FUNCTION MOBILITY AND FALL REDUCTION IN PATIENTS AFTER SURGICAL TREATMENT OF HIP FRACTURE | NOVARTIS PHARMACEUTICALS CORPORATION | $17,263 | 2 |
| AN OPEN LABEL LONG TERM STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF BYM338 IN PATIENTS WITH SPORADIC INCLUSION BODY MYOSITIS | NOVARTIS PHARMACEUTICALS CORPORATION | $4,163 | 2 |
| A 28 WEEK RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTI CENTER PARALLEL GROUP DOSE RANGE FINDING STUDY TO ASSESS THE EFFECT OF MONTHLY DOSES OF BIMAGRUMAB 70 210 AND 700 MG ON SKELETAL MUSCLE STRENGTH AND FUNCTION IN OLDER ADULTS WITH SARCOPENIA | NOVARTIS PHARMACEUTICALS CORPORATION | $1,763 | 2 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 2 PART ADAPTIVE DESIGN MULTICENTER 12 WEEK STUDY TO ASSESS SAFETY TOLERABILITY AND EFFICACY OF LJN452 IN PATIENTS WITH NON ALCOHOLIC STEATOHEPETATIS NASH | NOVARTIS PHARMACEUTICALS CORPORATION | $187.50 | 1 |
| CT-P6 3.2 | Celltrion, Inc. | $100.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 466 | 520 | $105,237 | $23,586 |
| 2022 | 14 | 680 | 897 | $141,834 | $30,042 |
| 2021 | 17 | 971 | 1,306 | $176,777 | $38,386 |
| 2020 | 20 | 944 | 1,331 | $196,992 | $43,575 |
Total Patients
3,061
Total Services
4,054
Medicare Billing
$135,589
Procedure Codes
77
All Medicare Procedures & Services
77 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 89 | 112 | $23,037 | $7,714 | 33.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 69 | 77 | $23,100 | $3,951 | 17.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 75 | 82 | $12,135 | $3,812 | 31.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 54 | 55 | $21,950 | $3,570 | 16.3% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 21 | 21 | $9,450 | $1,666 | 17.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 18 | 32 | $5,120 | $1,163 | 22.7% |
| 93350 | Ultrasound of heart during rest, exercise and/or drug-induced stress with report | Office | 2023 | 12 | 12 | $3,540 | $556.02 | 15.7% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 21 | 21 | $1,680 | $278.00 | 16.5% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 20 | 20 | $1,100 | $193.60 | 17.6% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 12 | 12 | $1,140 | $182.38 | 16.0% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Office | 2023 | 11 | 11 | $1,020 | $166.98 | 16.4% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 12 | 12 | $780.00 | $131.40 | 16.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 14 | 15 | $525.00 | $95.70 | 18.2% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Office | 2023 | 16 | 16 | $330.00 | $54.66 | 16.6% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 22 | 22 | $330.00 | $51.03 | 15.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 77 | 88 | $18,524 | $5,958 | 32.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 114 | 132 | $20,775 | $5,821 | 28.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 64 | 66 | $22,935 | $3,784 | 16.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 70 | 71 | $19,875 | $3,548 | 17.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 35 | 64 | $17,600 | $3,541 | 20.1% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2022 | 27 | 27 | $11,340 | $2,259 | 19.9% |
| 93350 | Ultrasound of heart during rest, exercise and/or drug-induced stress with report | Office | 2022 | 26 | 26 | $7,140 | $1,279 | 17.9% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2022 | 11 | 159 | $7,155 | $1,253 | 17.5% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2022 | 27 | 28 | $2,380 | $458.01 | 19.2% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2022 | 28 | 28 | $1,960 | $394.10 | 20.1% |
About Dr. Krishna Rao, M.D
Dr. Krishna Rao, M.D is a Cardiovascular Disease healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417925397.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Krishna Rao, M.D has received a total of $23,550 in payments from pharmaceutical and medical device companies, with $15.95 received in 2023. These payments were reported across 11 transactions from 5 companies. The most common payment nature is "" ($23,475).
As a Medicare-enrolled provider, Rao has provided services to 3,061 Medicare beneficiaries, totaling 4,054 services with total Medicare billing of $135,589. Data is available for 4 years (2020–2023), covering 77 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Rochester, NY
- Active Since 03/08/2006
- Last Updated 07/05/2023
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1417925397
Products in Payments
- BIMAGRUMAB (Biological) $23,188
- LJN452 (Drug) $187.50
- Ovation (Device) $37.85
- Edora 8 DR-T (Device) $21.27
- Repatha (Biological) $15.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Rochester
Samuel Asirvatham, M.d, M.D
Cardiovascular Disease — Payments: $1.5M
Cardiovascular Disease $1.5M
Srijoy Mahapatra, M.d, M.D
Cardiovascular Disease — Payments: $1.2M
Cardiovascular Disease $1.2M
Amir Lerman, M.d, M.D
Cardiovascular Disease — Payments: $590,259
Cardiovascular Disease $590,259
Charanjit Rihal, M.d, M.D
Cardiovascular Disease — Payments: $484,688
Cardiovascular Disease $484,688
Martha Grogan, M.d, M.D
Cardiovascular Disease — Payments: $402,326
Cardiovascular Disease $402,326
David Hayes, M.d, M.D
Cardiovascular Disease — Payments: $278,959
Cardiovascular Disease $278,959